All Access

Biotech Deals

Biotech Deals Alert

Alert

Multiply Labs, a physical AI company for medicine manufacturing, raised a $75 million Series B round, CEO Fred Parietti tells Axios Pro.

Why it matters: Drugmakers are increasingly applying AI and automation to biologics manufacturing.

How it works: The San Francisco-based company builds robotic systems that automate manual steps inside pharmaceutical manufacturing facilities.

Its systems are used across biologics manufacturing, including cell and gene therapies.

The intrigue: Parietti says Multiply recruited its supply chain team from Ferrari's Formula One operation.

Follow the money: NantWorks led, joined by AstraZeneca Ventures, Lingotto, Legend Biotech, Fifty Years Ventures, Ora Global, Teradyne Ventures, Strange Ventures, Casdin Capital, Lux Capital and Founders Fund.

AstraZeneca is also a Multiply customer, and Parietti says the company expects additional commercial partnerships tied to investors in the round.

State of play: Biologics manufacturing still requires highly trained workers to oversee sterile products.

Bristol Myers Squibb says its Devens, Massachusetts, plant increased production volume by more than 40% after deploying more than 30 AI and digital applications.

"Scientists want to discover drugs," Parietti says. "They want to make the first one, not the 10,000th one."

What's next: Multiply Labs will use proceeds to scale robot production and accelerate deployment, while expanding beyond cell therapy into other biologics.

Parietti says the company also expects to announce two more large pharmaceutical customers.

Multiply Labs raises $75M to scale pharma manufacturing robots

The round will help scale robot production and expand its automation systems.

Illustration of a robotic hand holding up a red velvet pillow with a vial of medicine in the center. 

Multiply Labs, a physical AI company for medicine manufacturing, raised a $75 million Series B round, CEO Fred Parietti tells Axios Pro.Why it matters: Drugmakers are <a class="gtmContentClick" data-vars-link-text="increasingly" data-vars-click-url="https://www.axios.com/2026/07/20/artificial-intelligence-drug-development-impact" data-vars-content-id="f51f77b5-a245-467c-8907-61877f78c0d0" data-vars-headline="Multiply Labs raises $75M to scale pharma manufacturing robots" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/2026/07/20/artificial-intelligence-drug-development-impact" target="_self">increasingly</a> applying AI and automation to biologics manufacturing.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

fort-lauderdale

cincinnati

scottsdale

boulder

kansas-city

austin

chicago

dallas

detroit

atlanta

indianapolis

nashville

nw-arkansas

columbus

hollywood

washington-dc

north-of-cincy

mesa

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

san-diego

tampa-bay

portland

cleveland

arapahoe

douglas

axios-local

axios-pro

axios-live

the-axios-show

Multiply Labs raises $75M to scale pharma manufacturing robots

What to read next